Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects

Sejung Hwang1, Jae-Wook Ko2, Heechan Lee3, Seokuee Kim3, Bongtae Kim3, Geun Seog Song3 and Jungryul Kim2,4*

1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea, 2Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, Seoul, South Korea, 3Division of Clinical Development, HK Inno.N Corporation, Seoul, South Korea, 4Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea

Potassium-competitive acid blocker is a new class of drugs inhibiting gastric acid. It is controversial that vonoprazan showed the inhibitory activities of cytochrome P450 3A4. This study aimed to evaluate the pharmacokinetics (PK) of atorvastatin and safety when atorvastatin was administered alone and co-administered with vonoprazan or tegoprazan. An open-label, multiple-dose, 3-intervention, 4-sequence, 4-period, partial replicate crossover study was conducted, and three interventions were: one is orally administered atorvastatin 40 mg alone once daily for 7 days, another is atorvastatin co-administered with vonoprazan 20 mg, and the other is atorvastatin co-administered with tegoprazan 50 mg. PK blood samples were collected up to 24 h after the last dose, and PK parameters for atorvastatin, 2-hydroxyatorvastatin and atorvastatin lactone were estimated by a non-compartmental method. Safety was evaluated, including adverse events and clinical laboratory tests. A total of 28 subjects completed the study. When atorvastatin was co-administered with vonoprazan, the systemic exposures of atorvastatin and atorvastatin lactone significantly increased, and the metabolic ratio of 2-hydroxyatorvastatin significantly decreased. Hypergastrinemia only occurred when atorvastatin was co-administered with vonoprazan. However, the plasma concentration profiles of atorvastatin, 2-hydroxyatorvastatin and atorvastatin lactone were similar when atorvastatin was administered alone or co-administered with tegoprazan. In conclusion, after multiple doses of atorvastatin co-administered with vonoprazan in healthy subjects, the systemic exposure of atorvastatin and the incidence of hypergastrinemia increased. With tegoprazan, however, those interactions were not observed.

Keywords: drug interactions, tegoprazan, vonoprazan, cytochrome P450 (CYP), pharmacokinetics, potassium-competitive acid blocker
INTRODUCTION

Proton pump inhibitors (PPIs) are commonly prescribed as the first-line drug for the treatment of acid-related diseases such as gastroesophageal reflux disease (GERD) by inhibiting H+/K+-ATPase (Katz et al., 2013; Otake et al., 2016). However, some limitations prevent PPIs from becoming the ideal antisecretory drugs. The major limitations are as follows: 1) PPIs are acid labile, 2) PPIs show a slow onset of action, taking 3–5 days for the appropriate effect, 3) PPIs show interindividual variations in pharmacokinetics (PK) according to cytochrome P450 (CYP) 2C19, and 4) PPIs fail to suppress nocturnal acid secretion expected by the short half-life (Otake et al., 2016).

Potassium-competitive acid blocker (P-CAB) is a new class of drugs that inhibits gastric H+/K+-ATPase (Inatomi et al., 2016). While PPIs require chemical conversion to their active form and only inhibit an activated form of H+/K+-ATPase, P-CAB does not require acid activation and reversely inhibits both an activated and inactivated form of H+/K+-ATPase by competitively blocking the potassium-binding site (Mori and Suzuki, 2019). Therefore, P-CAB shows a rapid onset of acid suppression and continuous acid suppression until the night compared to PPIs (Okuyama et al., 2017; Mori and Suzuki, 2019; Cho et al., 2020).

Vonoprazan, a P-CAB developed by Takeda Pharmaceutical Company, received approvals for acid-related diseases in some countries, including Japan and Korea (Inatomi et al., 2016). Tegoprazan, a P-CAB developed by HK inno.N, was recently approved to treat acid-related diseases such as GERD (Lee et al., 2019). Vonoprazan and tegoprazan are mainly metabolized by CYP3A4 and partially by CYP2B6, 2C19, 2D6.

A recent study suggested the potential that vonoprazan acts as a moderate inhibitor of CYP2C19 and CYP3A4 (Otake et al., 2016; Kagami et al., 2018). The results of in vitro studies indicated that vonoprazan could inhibit the metabolism of midazolam, the substrate of CYP3A4, and venlafaxine, the substrate of CYP3A4 and CYP2D6. In addition, the in vivo studies supported the results of the in vitro studies, which implicated the drug-drug interactions between vonoprazan and the substrates of CYP3A4 (Chen et al., 2020; Wang et al., 2020). The half-maximal inhibitory concentration (IC50) value of CYP3A4 for vonoprazan was 29 μM, and this value is thought to be much higher than the plasma concentration of vonoprazan at clinical doses (Nishihara et al., 2019). However, the potential CYP3A4 inhibitory effect of vonoprazan on drugs having first-pass effect is unknown. Although tegoprazan showed various inhibitory activities to organic anion transporting polypeptides (OATP) 1B1 according to the in vitro study, the systemic exposure of the substrates would not significantly increase considering the maximum concentration of tegoprazan at clinical doses (HK inno.N Corp).

One of the substrates of CYP3A4 and OATP1B1 is 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors, including atorvastatin (US Food and Drug Administration, 2020a). The bioavailability of atorvastatin is approximately 14%, and this low bioavailability is attributed to first-pass metabolism in the intestinal mucosa and the liver, in which CYP3A4 is involved (Lennernäs, 2003). When absorbed through the intestine, 76% of orally administered atorvastatin is lost in the gut, and 42% of the remaining amount is lost in the liver (Lennernäs, 2003). Therefore, when atorvastatin was co-administered with a potent CYP3A4 inhibitor such as itraconazole, the systemic exposure of atorvastatin increased, and the systemic exposure of 2-hydroxyatorvastatin, a metabolite of atorvastatin, decreased (Teemu Kantola, 1998; Jacobson, 2004).

The number of PPI users increased 10.6 times over 12 years, and the prescription rate of atorvastatin generally increased over 13 years (Kim et al., 2018; Son and Bae, 2019). PPIs and HMG-CoA reductase inhibitors are frequently co-administered with clopidogrel in Korea (Kim et al., 2019). The frequency of co-administering PPIs and atorvastatin would increase over time, and thus it is necessary to evaluate the drug interactions between P-CABs and atorvastatin. This study aimed to evaluate the PK of atorvastatin and safety profile when co-administered with P-CABs, vonoprazan or tegoprazan.

MATERIALS AND METHODS

Study Design and Interventions

This was an open-label, multiple-dose, 3-intervention, 4-sequence, 4-period, partial replicate crossover study (ClinicalTrials.gov Identifier: NCT04221321). The study protocol was approved by the institutional review board at Samsung Medical Center (Seoul, Republic of Korea) and the Ministry of Food and Drug Safety. All subjects gave written informed consent.

There were three interventions in this study, and daily administration for 7 days of atorvastatin 40 mg (LIPITOR®, Pfizer Inc., NY, United States) alone was defined as intervention R. Moreover, atorvastatin 40 mg co-administered with tegoprazan 50 mg (K-CAB®, HK inno.N Corporation, Republic of Korea) and atorvastatin 40 mg co-administered with vonoprazan 20 mg (TAKECAB®, Takeda Pharmaceutical Company Limited, Japan) was named as intervention T and intervention V, respectively. Among three interventions, subjects received intervention R twice and received intervention T and V once each. Subjects were allocated to one of the four sequences: T-R-V-R, R-T-R-V, R-V-R-T, and V-R-T-R (Figure 1). There were washout periods of 7–9 days between each intervention. Furthermore, this study was carried out in three groups since entire subjects could not be studied simultaneously. Assuming the within-subject coefficient of variation (CV) of atorvastatin as 40 and 15% as dropout rate, the planned sample size was 36 subjects providing more than 80% statistical power with a significance level of 0.05 to demonstrate 33% difference of PK parameter by drug interactions (Tothfalusi and Endrenyi, 2012).

Subjects

This study enrolled healthy male subjects aged 19–55 years with a body mass index of 19–27 kg/m². Major exclusion criteria were: a history of genetic myopathy or family history; a history of taking
any medications or foods that could significantly affect the PK of atorvastatin within 30 days before the randomization; blood aspartate aminotransferase, alanine aminotransferase or gamma-glutamyltransferase levels exceeding 1.5 times the upper limit of the reference range; an estimated glomerular filtration rate less than 60 ml/min/1.73 m².

Procedure and Assessments
Subjects had scheduled visits on the morning of Days 1–4 for dosing and then were admitted to the Clinical Trial Center of Samsung Medical Center on the evening of Day 4. Subjects received the study drug orally with water of 150 ml after an overnight fast of at least 10 h on Days 5–7 and were required to fast for an additional 4 h postdose on Day 7.

Serial blood samples were collected for PK assessment before dosing and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 9, 12, 15, and 24 h after the last repeated dose (Day 7). Blood samples were centrifuged at approximately 1,800 g for 10 min at 4°C, and then the plasma samples were stored at less than -70°C until the assays.

Safety was assessed based on symptom reports, physical examinations, vital signs, 12-lead ECGs, and clinical laboratory tests (hematology, clinical chemistry, and urinalysis).

Assay of Atorvastatin and Its Metabolites
Plasma samples for atorvastatin, 2-hydroxyatorvastatin and atorvastatin lactone were analyzed with ultra-performance liquid chromatography (Waters ACQUITY UPLC® System; Waters, Milford, MA) - tandem quadruple spectrometry (Waters XevoTM TQ-XS MS; Waters, Milford, MA) method.

Atorvastatin-d₅, 2-hydroxyatorvastatin-d₅ and atorvastatin lactone-d₅ were used as the internal standard. The range for quantification was 0.100–200 ng/ml for atorvastatin, 0.0500–100 ng/ml for 2-hydroxyatorvastatin and atorvastatin lactone. The correction coefficients (r²) were greater than 0.99 over these concentration ranges. The precision and accuracy for mean within-run data and mean between-run data of all analytes were determined using the percentage of relative SD (%RSD) and the percentage of deviation of the mean from theoretical (%DMT).

The precision and accuracy for mean within-run data on atorvastatin in quality control (QC) samples (concentration range, 0.100–150 ng/ml) ranged from 0.6 to 2.7 and -1.6 to 1.5, respectively. The precision and accuracy for mean between-run data on atorvastatin in QC samples were determined from 1.1 to 2.5 and from −2.9 to −0.3, respectively. Based on back-calculated concentration, the between-run precision and accuracy ranged from 0.3 to 1.6 and from −1.8 to 2.1, respectively.

The within-run precision and accuracy for two metabolites in QC samples (concentration range, 0.0500–75.0 ng/ml) ranged from 0.4 to 4.6 and −3.0 to 0.7 on 2-hydroxyatorvastatin, respectively, and from 1.5 to 2.3 and 1.4 to 7.3 on atorvastatin lactone, respectively. The between-run precision and accuracy in QC samples were determined from 0.9 to 4.9 and −2.0 to −0.5 on 2-hydroxyatorvastatin, respectively, and from 2.1 to 2.8 and −1.9 to 5.0 on atorvastatin lactone, respectively. Based on back-calculated concentration, the between-run precision and accuracy were in a range of...
0.5–2.4 and −0.8–0.8 on 2-hydroxyatorvastatin and 1.2–3.7 and -3.8–4.5 on atorvastatin lactone, respectively.

Statistical Analysis

The PK profiles of atorvastatin and its metabolites were evaluated based on the following parameters: the maximum plasma concentration (C_{ss,max}) and area under the concentration-time curve (AUC_{τ}) at steady state for each analyte, time to C_{ss,max} (T_{ss,max}) for atorvastatin, and metabolic ratio for atorvastatin metabolites. The PK parameters were obtained directly from the data or estimated by a non-compartmental method using MATLAB SimBiology (The MathWorks, Inc, 2020). The descriptive statistics for the PK parameters were summarized by the intervention, and the comparison of PK parameters was performed on C_{ss,max} and AUC_{τ}. Log-transformed C_{ss,max} and AUC values were assessed by a mixed-effects model. The model defined sequence, group, period nested in group and intervention as fixed effects and subject as a random effect, where the cluster of subjects studied at one time was reflected in the group effect. Intervention R was considered a reference in this analysis, and no adjustment was made for multiple comparisons unless otherwise specified. Subject characteristics and adverse events (AEs) were also summarized. The changes in serum gastrin, pepsinogen I and II levels were compared by mixed-effects model with Tukey-Kramer method. To explore the effect of co-administered with tegoprazan or vonoprazan on the low-density lipoprotein cholesterol (LDL-C) lowering effect of atorvastatin (Kenward et al., 2010), the changes of LDL-C were compared between the interventions by mixed-effects model and the post-hoc analysis was performed using Tukey-Kramer method. Statistical analysis was carried out using SAS Enterprise Guide (Version 7.1; SAS Institute Inc., NC, United States) with a significance level of 0.05.

RESULTS

Study Population

A total of 32 subjects were enrolled, and 28 subjects completed the study (Figure 1). One subject withdrew the consent before the investigational product administration, and 3 subjects discontinued the study due to AEs (2 subjects) and the physician decision (1 subject). Twenty-eight subjects, who had complete PK profiles, were included for PK analysis and safety was analyzed in 31 subjects (31 subjects in intervention R1, 28 subjects in intervention R2, 30 subjects in intervention T, and 29 subjects in intervention V) who had received any intervention at least once. The mean (±standard deviation) values of age, weight, height, and body mass index (BMI) of the 32 enrolled subjects were 33.9 (±9.6) years, 71.1 (±8.1) cm, 174.6 (±6.0) kg, and 23.3 (±2.6) kg/m². The demographic characteristics were similar among the allocation groups.

Pharmacokinetics

Mean plasma concentration profiles of atorvastatin when atorvastatin was administered alone and co-administered with vonoprazan or tegoprazan are shown in Figure 2A. For better visual inspection of the absorption phase of atorvastatin, the mean plasma concentration profiles of atorvastatin up to 4 h are represented in Figure 2B.

When atorvastatin was co-administered with vonoprazan, the C_{ss,max} of atorvastatin increased by 17% and AUC_{τ} of atorvastatin increased by 28% compared to those when atorvastatin was administered alone (Table 2). Although the systemic exposure of atorvastatin increased, the C_{ss,max} and AUC_{τ} of 2-hydroxyatorvastatin decreased by 30 and 9%, respectively, when atorvastatin was co-administered with vonoprazan compared to those when administered alone (Supplementary
FIGURE 3 | Mean plasma concentration-time profiles of 2-hydroxyatorvastatin and atorvastatin lactone up to 4 h after oral administration of atorvastatin alone once a day for 7 days (Reference 1, 2) and co-administered with tegoprazan (Tegoprazan) or vonoprazan (Vonoprazan) for 7 days. Bars represent standard deviations. 

TABLE 1 | Pharmacokinetic parameters of atorvastatin and metabolites (2-hydroxy atorvastatin, atorvastatin lactone) after oral administration of atorvastatin for 7 days administered alone and co-administered with tegoprazan or vonoprazan.

| Parameters                  | Reference 1 (N = 28) | Reference 2 (N = 28) | Tegoprazan (N = 28) | Vonoprazan (N = 28) |
|-----------------------------|----------------------|----------------------|---------------------|---------------------|
| Atorvastatin                |                      |                      |                     |                     |
| T_{ss,max} (h)*             | 0.75 (0.50–6.00)     | 0.75 (0.50–3.00)     | 1.25 (0.50–3.00)    | 1.50 (0.50–4.00)    |
| C_{ss,max} (μg/L)           | 37.21 ± 19.65        | 37.37 ± 22.81        | 40.75 ± 21.52       | 42.71 ± 25.76       |
| AUC_{τ} (h·μg/L)            | 125.61 ± 67.08       | 124.24 ± 61.34       | 130.26 ± 71.17      | 159.78 ± 82.11      |
| 2-hydroxyatorvastatin       |                      |                      |                     |                     |
| C_{ss,max} (μg/L)           | 24.95 ± 11.77        | 25.72 ± 17.15        | 26.34 ± 12.64       | 18.19 ± 12.16       |
| AUC_{τ} (h·μg/L)            | 152.04 ± 70.25       | 144.35 ± 58.71       | 156.46 ± 67.89      | 135.57 ± 64.05      |
| Metabolic ratio             | 1.27 ± 0.52          | 1.32 ± 0.35          | 1.31 ± 0.47         | 0.90 ± 0.32         |
| Atorvastatin lactone        |                      |                      |                     |                     |
| C_{ss,max} (μg/L)           | 8.12 ± 4.78          | 7.91 ± 4.9           | 8.34 ± 5.04         | 10.39 ± 5.46        |
| AUC_{τ} (h·μg/L)            | 61.07 ± 30.20        | 57.36 ± 28.51        | 59.62 ± 30.99       | 74.97 ± 32.03       |
| Metabolic ratio             | 0.52 ± 0.21          | 0.49 ± 0.20          | 0.51 ± 0.23         | 0.51 ± 0.20         |

Notes: Reference 1, the first intervention of atorvastatin administered alone; Reference 2, the second intervention of atorvastatin administered alone; Tegoprazan, co-administration of atorvastatin and tegoprazan once a day for 7 days; Vonoprazan, co-administration of atorvastatin and tegoprazan once a day for 7 days.

Values are presented as mean ± standard deviation. The metabolic ratio was calculated by AUC_{metabolite}/AUC_{atorvastatin}.

*Values are presented as median (minimum–maximum).

Abbreviations: AUC_{τ}, area under the curve over a dosing interval at steady state; C_{ss,max}, maximum concentration at steady state; T_{ss,max}, time of C_{max} at steady state.

TABLE 2 | Comparison of pharmacokinetic parameters of atorvastatin after oral doses of atorvastatin for 7 days administered alone and co-administered with tegoprazan or vonoprazan.

| Parameters                  | Geometric least squares mean | GMR (90% CI) | Geometric least squares mean | GMR (90% CI) |
|-----------------------------|-----------------------------|-------------|-----------------------------|-------------|
|                            | With Tegoprazan (N = 28)    | Atorvastatin alone (N = 28 for each intervention) | With Vonoprazan (N = 28) | Atorvastatin alone (N = 28 for each intervention) |
| C_{ss,max} (μg/L)           | 35.4                       | 32.4        | 1.09 (0.97–1.23)            | 37.9        | 32.4        | 1.17 (1.04–1.32)* |
| AUC_{τ} (h·μg/L)            | 114.9                      | 112.0       | 1.03 (0.96–1.08)            | 143.4       | 112.0       | 1.26 (1.22–1.34)* |

Tegoprazan, co-administration of atorvastatin and tegoprazan once a day for 7 days; Vonoprazan, co-administration of atorvastatin and tegoprazan once a day for 7 days.

GMR is calculated as a ratio of atorvastatin co-administered with tegoprazan or vonoprazan to administered alone.

*According to the equivalence test, if the 90% confidence interval is not included in the predefined equivalence range (0.8–1.25), it is not considered equivalent.

Abbreviations: AUC_{τ}, area under the curve over a dosing interval at steady state; C_{ss,max}, maximum concentration at steady state; CI, confidence interval; GMR, the geometric mean ratio.
Table S1). The mean plasma concentration profiles up to 4 h showed that 2-hydroxyatorvastatin was formed more slowly than when atorvastatin was administered alone (Figure 3A). The $C_{\text{ss,max}}$ and $\text{AUC}_\tau$ of atorvastatin lactone increased by 32 and 29% respectively when atorvastatin was co-administered with vonoprazan compared to those when atorvastatin was administered alone (Supplementary Table S1). The noticeable increase of $C_{\text{ss,max}}$ of atorvastatin lactone was also observed in the mean plasma concentration profiles up to 4 h (Figure 3B).

However, the metabolic ratio of atorvastatin lactone was similar between the intervention groups since the systemic exposure of atorvastatin lactone increased to a similar extent to that of atorvastatin (Table 1). When atorvastatin was co-administered with tegoprazan, the $C_{\text{ss,max}}$ and $\text{AUC}_\tau$ of atorvastatin were similar to those when atorvastatin was administered alone (Table 1, Table 2). Moreover, there was no difference in the mean plasma concentration profiles of atorvastatin up to 4 h (Figure 2B).

The $C_{\text{ss,max}}$ and $\text{AUC}_\tau$ of 2-hydroxyatorvastatin and atorvastatin lactone were similar regardless of the tegoprazan co-administration (Supplementary Table S1).

### Safety and Tolerability

A total of 42 treatment-emergent AEs (TEAEs) was reported in 22 (68.8%) of the 31 subjects. Seven TEAEs occurred in 6 subjects (19.4%) in the intervention R1, and 8 TEAEs occurred in 7 subjects (25.5%) in the intervention R2. Ten TEAEs occurred in 7 subjects (23.3%) in the intervention T, and 17 TEAEs occurred in 15 subjects (51.7%) in the intervention V. Two subjects discontinued the study due to AEs (neutropenia for 1 subject in the intervention T, blood creatine phosphokinase increased for 1 subject in the intervention R). Among the 42 TEAEs, 3 TEAEs were moderate, and 1 TEAE (blood creatine phosphokinase increased) was severe in intensity while the others were mild. Of the 42 TEAEs, 33 cases were evaluated as possibly related to the intervention.

Frequently reported TEAEs were hypergastrinemia (6 cases), blood bilirubin increased (6 cases), and pyuria (5 cases). Hypergastrinemia, defined by a serum gastrin level greater than 200 ng/L, only occurred when atorvastatin was co-administered with vonoprazan. The serum gastrin, pepsinogen I and II levels overall increased after the administration of tegoprazan or vonoprazan compared to the baseline (Figure 4). The increase of mean serum gastrin after the co-administration of vonoprazan was significantly different compared to other interventions (T vs. V, $p < 0.001$; R vs. V, $p < 0.001$). Additionally, there were significant differences in the extent of the increase in the serum pepsinogen I and II between vonoprazan and tegoprazan ($p < 0.001$ for pepsinogen I; $p < 0.001$ for pepsinogen II). Meanwhile, the changes of LDL-C were not significantly different between the interventions (R vs. T, $p = 0.347$; R vs. V, $p = 0.872$; T vs. V, $p = 0.858$).

The number of subjects with TEAEs when atorvastatin was administered alone (6 subjects in Reference 1 and 7 subjects in Reference 2) was similar to when atorvastatin was co-administered with tegoprazan (7 subjects). However, when
atorvastatin was co-administered with vonoprazan, more subjects (15 subjects) reported TEAEs than those when atorvastatin was administered alone (Table 3). There were no clinically significant changes in vital signs, physical examinations, and 12-lead ECGs.

**DISCUSSION**

This study investigated whether the concomitant administration of atorvastatin with P-CABs, tegoprazan or vonoprazan, influences the PK of atorvastatin and safety profile. Atorvastatin was known as a highly variable drug with a within-subject CV of more than 30%. Based on the previous replicate crossover studies of atorvastatin, the within-subject CV of C_{max} and AUC were 39–45% and 17–23%, respectively (Hwang et al., 2020; Kim et al., 2020). In the case of highly variable drugs such as atorvastatin, some regulatory agencies recommend a full or partial replicated crossover design (US Food and Drug Administration, 2001). Therefore, this study was designed as a partial replicated crossover study where subjects received intervention R twice and received intervention T and V once. In this study, the within-subject CV of C_{max} and AUC_{T} of atorvastatin were 33.6 and 11% (data not shown), slightly smaller than those of previous studies (38–44.1% for C_{max} and 16.7–15.5% for AUC) (Hwang et al., 2020; Kim et al., 2020). This difference might be mainly due to multiple doses of atorvastatin for 7 days, reducing the within-subject variability. The high variability in the plasma concentrations of atorvastatin, especially in the absorption phase, was also observed in other studies with similar standard deviations (Hwang et al., 2020; Kim et al., 2020).

Atorvastatin is orally administered in the hydroxy acid ring form and interconverted to the inactive lactone form, and both forms are metabolized to hydroxylated forms by CYP3A4 (Lennernäs, 2003; Hermann et al., 2006). In this study, co-administration of atorvastatin with vonoprazan increased the systemic exposure of atorvastatin and decreased the systemic exposure of 2-hydroxyatorvastatin, resulting in a significant decrease in the metabolic ratio of 2-hydroxyatorvastatin. When atorvastatin was co-administered with vonoprazan, 2-hydroxyatorvastatin was formed relatively slower than when atorvastatin was administered alone. In addition, the slopes of the elimination phase in the log-linear profiles were similar among all the intervention groups. Considering the high permeability of atorvastatin, the changes in the PK of atorvastatin reflected the changes in the activity of CYP3A4 which is independent of the permeability. The IC50 values of CYP3A4 for tegoprazan and vonoprazan were >30 and 29 μM, respectively, and the expected plasma concentrations of tegoprazan and vonoprazan when administered at clinical doses are 25-fold lower than the IC50 (Nishihara et al., 2019; HK inno.N Corp). However, when vonoprazan 20 mg is orally administered, the intestinal luminal concentration of vonoprazan is estimated to be approximately 232 μM that is 8-fold higher than the IC50 for vonoprazan (US Food and Drug Administration, 2020b). Vonoprazan with high luminal concentrations may inhibit the intestinal CYP3A4, thus increasing the systemic exposure of orally administered atorvastatin. Similarly, some clinical studies revealed that concurrent use of statins with CYP3A4 inhibitors, such as protease inhibitors and diltiazem, inhibited the intestinal CYP3A4 increasing systemic exposure of atorvastatin or simvastatin (W Jacobsen, 2000; Fichtenbaum CJ et al., 2002). These results indicated that vonoprazan would inhibit the intestinal CYP3A4, not the hepatic CYP3A4.

The atorvastatin lactone form is inactive in the effect of lowering lipid (Hermann et al., 2006). However, a recent study suggested that atorvastatin lactone might contribute to the occurrence of muscular adverse events such as myopathy (Hermann et al., 2006). Therefore, the effect of co-administration with tegoprazan or vonoprazan on the systemic exposure of atorvastatin lactone should be considered. The atorvastatin lactone is formed by uridine diphosphate–glucuronosyltransferase (UGT) 1A1 and UGT1A3 and sequentially metabolized to 2-, 4-hydroxyatorvastatin lactone by CYP3A4 (Lennernäs, 2003; Hermann et al., 2006). In this study, the systemic exposure of atorvastatin lactone significantly increased when atorvastatin was co-administered with vonoprazan. This increase implies that vonoprazan could inhibit CYP3A4 which involves the formation of 2-, 4-hydroxyatorvastatin lactone (Hermann et al., 2006). In contrast to 2-hydroxyatorvastatin, the metabolic ratio of atorvastatin lactone was similar between all

---

**Table 3** Summary of Treatment-emergent adverse events (TEAEs) reported by two or more subjects after oral administration of atorvastatin for 7 days administered alone and co-administered with tegoprazan or vonoprazan.

| Preferred term                  | Reference 1 (N = 31) | Reference 2 (N = 28) | Tegoprazan (N = 30) | Vonoprazan (N = 29) |
|--------------------------------|----------------------|----------------------|---------------------|--------------------|
| Blood bilirubin increased      | 1 (3.2) [1]          | 2 (7.1) [2]          | 2 (6.7) [2]         | 1 (3.4) [1]        |
| Hypergastrinaemia              |                      |                      |                     | 6 (20.7) [8]       |
| Pyuria                         | 1 (3.2) [1]          | 1 (3.6) [1]          | 1 (3.3) [1]         | 2 (6.9) [2]        |
| Neutrophil count decreased     |                      |                      | 1 (3.3) [1]         | 2 (6.9) [2]        |
| Dyspepsia                      |                      |                      |                     | 2 (6.9) [2]        |
| Headache                       |                      |                      |                     | 2 (6.9) [2]        |
| Anaemia                        | 1 (3.2) [1]          | 1 (3.6) [1]          | −                   | −                  |
| Ocular discomfort              | 1 (3.2) [1]          | −                    | 1 (3.3) [1]         | −                  |

Notes: Reference 1, the first intervention of atorvastatin administered alone; Reference 2, the second intervention of atorvastatin administered alone; Tegoprazan, co-administration of atorvastatin and tegoprazan once a day for 7 days; Vonoprazan, co-administration of atorvastatin and tegoprazan once a day for 7 days.

Values are presented as number of subjects (percentage of subjects with AEs) [number of events].
intervention groups. According to this study, it is confirmed that vonoprazan and tegoprazan do not affect UGT1A1 and UGT1A3.

The liver-specific transporter OATP1B1, uptaking endogenous compounds and drugs into hepatocytes, plays an important role in eliminating atorvastatin and its metabolites (Lau et al., 2007). The endogenous bile acid derivative bilirubin is one of the substrates of OATP1B1 like atorvastatin (Lau et al., 2007). Co-administration of atorvastatin with OATP1B1 inhibitors increased the systemic exposure of atorvastatin and induced transient hyperbilirubinemia (Lau et al., 2007). Although tegoprazan showed the inhibitory activity on some OATP1B1 substrates in a non-clinical study, the systemic exposure of the substrates would not significantly increase considering the maximum concentration of tegoprazan at clinical doses (HK inno.N Corp). In this study, when atorvastatin was co-administered with tegoprazan, the C_{ss,max} and AUC of atorvastatin increased by 9 and 3%, respectively. These increases were not clinically significant since none of them were statistically significant and the within-subject CVs of the C_{ss,max} and AUC of atorvastatin are known to be high (Hwang et al., 2020; Kim et al., 2020). Thus tegoprazan would not have any effect on OATP1B1 at clinical dose. Also, the in vitro study showed that vonoprazan did not inhibit OATP1B1 (Pharmaceuticals and Medical Devices Agency, 2014). The increase in the blood bilirubin in this study was similar regardless of whether atorvastatin was administered alone or in combination with P-CABs. Accordingly, the increase of the systemic exposure of atorvastatin co-administered with vonoprazan in this study resulted from inhibiting CYP3A4, not attributed to the inhibition of OATP1B1.

It is important whether the changes of PK by drug-drug interactions affect the efficacy. The dose-response of atorvastatin generally shows a log-linear profile, but the PK is not directly correlated with the LDL-C lowering effect of atorvastatin (Lennernäs, 2003). As expected, the changes of serum LDL-C levels were not statistically different between the interventions in this study. However, further studies are needed to determine the impact of these interactions on LDL-C levels in patients with dyslipidemia since this study was conducted in healthy adults.

Some studies showed that serum gastrin, pepsinogen I and II increased after P-CAB treatment (Inatomi et al., 2016), and hypergastrinemia could be observed frequently when PPIs, including P-CABs, are administered (Mori and Suzuki, 2019; Cho et al., 2020). Given the mechanism of action of the PPIs and subsequent physiological feedback increasing serum gastrin to lower gastric pH, hypergastrinemia can be predictable. Nonetheless, the serum gastrin increased only 1.2 times higher when atorvastatin was co-administered with tegoprazan. Similarly, other studies reported that tegoprazan as well as other gastric acid inhibitors did not compensatively increase the serum gastrin level (Sunwoo et al., 2020; Cho et al., 2020). The mechanism by which tegoprazan does not increase the serum gastrin level has not yet been elucidated.

The gastrin stimulates the pepsinogen release from chief cells and the increase of pepsinogen I and II is predictable (Qian et al., 1993). In this study, the levels of pepsinogen I and II significantly increased when atorvastatin was co-administered with tegoprazan or vonoprazan compared to when atorvastatin was administered alone. However, when atorvastatin was co-administered with vonoprazan, the increases in serum pepsinogen I and II were much greater than those when atorvastatin was co-administered with tegoprazan (5.6 and 5.4 times with vonoprazan, respectively; 2.7 and 2.2 times with tegoprazan). Although the serum gastrin level did not significantly increase when atorvastatin was co-administered with tegoprazan, the serum pepsinogen I and II level could increase since the release of pepsinogen is effectively stimulated by other factors such as cholecystokinin.

The increased blood bilirubin was also frequently observed in this study. Regardless of whether tegoprazan or vonoprazan was co-administered, this might be associated with the administration of atorvastatin. Although the incidence of TEAEs between those of atorvastatin administered alone and co-administered with tegoprazan was similar, more subjects reported TEAEs when atorvastatin was co-administered with vonoprazan. Except for the hypergastrinemia, the safety and tolerability profiles were similar among the interventions. Myopathy, which might progress to life-threatening rhabdomyolysis, is one of the remarkable adverse effects of atorvastatin (Lennernäs, 2003). Although the mechanism of statin-induced muscle adverse events is not fully understood, the risk of the adverse events is thought to be associated with the systemic exposure of statin, especially atorvastatin lactone and 4-hydroxyatorvastatin (Hermann et al., 2006). The co-administration of CYP3A4 inhibitors with atorvastatin showed a higher risk of muscular adverse events such as myopathy and rhabdomyolysis (Hermann et al., 2006). Therefore, the further assessment that the co-administration of atorvastatin with vonoprazan potentially inhibits intestinal CYP3A4 should be conducted in terms of the efficacy and the adverse events.

In conclusion, the systemic exposure of atorvastatin and hypergastrinemia incidence increased after multiple doses of atorvastatin co-administered with vonoprazan in healthy subjects. There was no evidence of significant interactions when atorvastatin was co-administered with tegoprazan.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the institutional review board (IRB) at Samsung Medical Center (Seoul, Republic of Korea) and the Ministry of
Food and Drug Safety. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

J-WK and JK designed and conducted the study. SH and JK analyzed the data. SH, J-WK, JK, HL, SK, BK, and GS wrote the manuscript. All the authors reviewed and revised the manuscript and approved the final paper.

**FUNDING**

This study received funding from HK inno.N Corporation, Seoul, Republic of Korea. The funder was not involved in the study design, collection, analysis, interpretation of data or the decision to submit this article for publication.

**ACKNOWLEDGMENTS**

We acknowledge the investigators, coordinators, and co-workers in this study.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.754849/full#supplementary-material

Katz, P. O., Gerson, L. B., and Vela, M. F. (2013). Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. *Am. J. Gastroenterol.* 108 (3), 308–329. doi:10.1038/ajg.2012.444

Kenward, M. G., and Roger, J. H. (2010). The Use of Baseline Covariates in Crossover Studies. *Biostatistics* 11 (1), 1–17. doi:10.1093/biostatistics/kxp046

Kim, J. J., Jung, E. J., Jang, E. J., Kim, D. H., Park, H., and Sohn, H. S. (2018). Proton Pump Inhibitors’ Use in Korea Based on the National Health Insurance Sample Cohort Database (2002−2013). *Yakah Hoeji* 62 (3), 171–178. doi:10.17480/pk.2018.62.3.171

Kim, M. S., Song, H. J., Lee, J., Yang, B. R., Choi, N. K., and Park, B. J. (2019). Effectiveness and Safety of Clopidogrel Co-administered with Statins and Proton Pump Inhibitors: A Korean National Health Insurance Database Study. *Clin. Pharmacol. Ther.* 106 (1), 182–194. doi:10.1002/cpt.1361

Kim, S., Ko, J. W., and Kim, J. R. (2020). Pharmacokinetic and Safety Profiles of a Fixed-Dose Combination of Amlodipine, Valsartan, and Atorvastatin: A 3-Period Repeat Crossover Study. *Clin. Pharmacol. Drug Dev.* 9 (3), 386–394. doi:10.1002/cpdd.772

Lau, Y. Y., Huang, Y., Frassetto, L., and Benet, L. Z. (2007). Effect of OATP1B2 Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers. *Clin. Pharmacol. Ther.* 81 (2), 194–204. doi:10.1038/sj.clpt.6100386

Lee, K. I., Son, B. K., Kim, G. H., Jung, H. K., Jung, H. Y., Chung, I. K., et al. (2019). Randomised Phase 3 Trial: Tegoprazan, a Novel Potassium-Competitive Acid Blocker, vs. Esomeprazole in Patients with Erosive Oesophagitis. *Aliment. Pharmacol. Ther.* 47 (5), 864–872. doi:10.1111/apt.15185

Lennernäs, H. (2003). Clinical Pharmacokinetics of Atorvastatin. *Clin. Pharmacokinet.* 42 (13), 1141–1160. doi:10.2165/000211075.000000000-00000

Mori, H., and Suzuki, H. (2019). Role of Acid Suppression in Acid-Related Diseases: Proton Pump Inhibitor and Potassium-Competitive Acid Blocker. *J. Neurogastroenterol. Motil.* 25 (1), 6–14. doi:10.5056/jnm18139

Nishihara, M., Yamasaki, H., Czernecki, R., and Jenkins, H. (2019). *In Vitro* Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction between Vonoprazan and Clopidogrel. *Eur. J. Drug Metab. Pharmacokinet.* 44 (2), 217–227. doi:10.1007/s13318-018-0521-7

Okiyama, M., Nakahara, K., Isakura, N., Hasegawa, T., Oyama, Y., Inoue, A., et al. (2017). Factors Associated with Potassium-Competitive Acid Blocker Non-response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. *Digestion* 95 (4), 281–287. doi:10.1159/000475658

Otake, K., Sakurai, Y., Nishida, H., Fukui, H., Tagaya, Y., Yamasaki, H., et al. (2016). Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438). *Adv. Ther.* 33 (7), 1140–1157. doi:10.1007/s12325-016-0345-2

Pharmaceuticals and Medical Devices Agency (2014). Review Report for Takecab Tablets. Available at: https://www.pmda.go.jp/files/000211075.pdf (Accessed July 15, 2021).

Qian, J. M., Rowley, W. H., and Jensen, R. T. (1993). Gastrin and CCK Activate Phospholipase C and Stimulate Pepsinogen Release by Interacting with Two

---

For the full references, please refer to the provided list at the end of the text.
Distinct Receptors. *Am. J. Physiol.* 264 (4 Pt 1), G718–G727. doi:10.1152/ajpgi.1993.264.4.G718

Son, K. B., and Bae, S. (2019). Patterns of Statin Utilisation for New Users and Market Dynamics in South Korea: a 13-year Retrospective Cohort Study. *BMJ Open* 9 (3), e026603. doi:10.1136/bmjopen-2018-026603

Sunwoo, J., Ji, S. C., Oh, J., Ban, M. S., Nam, J. Y., Kim, B., et al. (2020). Pharmacodynamics of Tegoprazan and Revaprazan after Single and Multiple Oral Doses in Healthy Subjects. *Aliment. Pharmacol. Ther.* 52 (11-12), 1640–1647. doi:10.1111/apt.16121

The MathWorks, Inc (2020). *SimBiology: User’s Guide*. Natick, MA: MathWorks®.

Tothfalusi, L., and Endrenyi, L. (2012). Sample Sizes for Designing Bioequivalence Studies for Highly Variable Drugs. *J. Pharm. Pharm. Sci.* 15 (1), 73–84. doi:10.18433/j3z88f

US Food and Drug Administration. (2001). Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Available at: https://www.fda.gov/media/70958/download (Accessed July 15, 2021).

US Food and Drug Administration. (2020a). Clinical Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter- Mediated Drug Interactions. Available at: https://www.fda.gov/media/134581/download (Accessed July 15, 2021).

US Food and Drug Administration. (2020b). *In Vitro Drug Interaction Studies Cytochrome P450 Enzyme and Transporter Mediated Drug Interactions*. Available at: https://www.fda.gov/media/134582/download (Accessed July 15, 2021).

Wang, Y., Wang, C., Wang, S., Zhou, Q., Dai, D., Shi, J., et al. (2020). Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. *Front. Pharmacol.* 11, 53. doi:10.3389/fphar.2020.00053

**Conflicts of Interest:** HL, SK, BK, and GS Song are currently employed by HK inno.N Corporation.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2021 Hwang, Ko, Lee, Kim, Song and Kim.** This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.